Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05908734 · ClinicalTrials.gov registry record · Phase 1

A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer

A Phase 1 study of Carcinoma, Non-Small Cell Lung, sponsored by Janssen Research & Development.

Active
Registry status
Phase 1
Development phase
71
Enrollment target
20
Study locations

NCT05908734 is a Phase 1 study of Carcinoma, Non-Small Cell Lung that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 71 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05908734, a Phase 1 study of Carcinoma, Non-Small Cell Lung, is active but no longer recruiting, sponsored by Janssen Research & Development.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
71 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and cetrelimab combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination at the selected RP2CD in participants with NSCLC characterized on the basis of epidermal growth factor receptor (EGFR) and Programmed-cell death Ligand (PD-L)1 status, in the Phase 2 (expansion).

Conditions Studied

Carcinoma, Non-Small Cell Lung

Interventions

  • DRUG Amivantamab
  • DRUG Cetrelimab

Study Locations (20)

Other

  • Fundacao Pio XII - Barretos
  • Cetus Oncologia - Belo Horizonte
  • PERSONAL Oncologia de Precisao e Personalizada - Belo Horizonte
  • CIONC Centro Integrado de Oncologia de Curitiba - Curitiba
  • Hospital do Cancer de Londrina - Londrina
  • Hospital Nossa Senhora da Conceicao S A - Porto Alegre
  • Hospital Santa Izabel Santa Casa de Misericordia da Bahia - Salvador
  • Fundacao Antonio Prudente A C Camargo Cancer Center - São Paulo
  • European Institute of Oncology - Milan
  • ASST Grande Ospedale Metropolitano Niguarda - Milan
  • Aou San Luigi Gonzaga - Orbassano
  • Centro Ricerche Cliniche di Verona S r l - Verona
  • University Malaya Medical Centre - Kuala Lumpur

California

  • City of Hope - Duarte
  • City of Hope Orange County Lennar Foundation Cancer Center - Irvine
  • Cancer and Blood Specialty Clinic - Los Alamitos

Oregon

  • Providence Portland Medical Center - Portland
  • Providence Oncology and Hematology Care Clinic Westside - Portland

Texas

  • MD Anderson Cancer Center - Houston

Virginia

  • Virginia Cancer Specialists - Fairfax

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2023-05-18
Est. Completion 2027-03-31
Phase Phase 1

Sponsor

Janssen Research & Development

593 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05908734

The ClinicalTrials.gov registry entry for NCT05908734 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (78% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which Amivantamab is the first listed.

NCT05908734 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Oregon.

Frequently Asked Questions

What is clinical trial NCT05908734 about?

NCT05908734 is a clinical study titled "A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer". The purpose of this study is to identify the recommended Phase 2 (combination) dose (RP2CD) of the amivantamab and cetrelimab combination therapy in participants with non-small cell lung cancer (NSCLC) in Phase 1 (combination dose selection); and to evaluate the antitumor effect of the combination a...

What is the current status of trial NCT05908734?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2023-05-18. Estimated completion is 2027-03-31.

What conditions does trial NCT05908734 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

What interventions are being tested in trial NCT05908734?

The interventions under investigation include: Amivantamab (DRUG), Cetrelimab (DRUG).

Who is sponsoring clinical trial NCT05908734?

This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05908734 being conducted?

This trial has 20 study locations across California, Oregon, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.